Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Johnson

Showing results (101-110 of 190) with videos related to

Pageof 19
Sort By:
Exploratory Research in Clinical and Social Pharmacy|July 31, 2023
Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritisYinan Huang, Satabdi Chatterjee, Sandeep K Agarwal, et al.
Journal of the American Geriatrics Society|December 2, 2021
Risk of overactive bladder associated with cholinesterase inhibitors in dementiaPrajakta P Masurkar, Satabdi Chatterjee, Jeffrey T Sherer, et al.
Drugs & Aging|March 25, 2021
Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort StudySanika Rege, Ryan M Carnahan, Michael L Johnson, et al.
Journal of Alzheimer'S Disease : JAD|November 1, 2015
Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and HypertensionHemalkumar B Mehta, Vinay Mehta, Chu-Lin Tsai, et al.
Journal of Diabetes and Its Complications|May 30, 2025
Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes patientsZahra Majd, Hua Chen, Michael L Johnson, et al.
Journal of Psychiatric Research|August 5, 2019
Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's diseaseFarid Chekani, Holly M Holmes, Michael L Johnson, et al.
Cancers|June 27, 2024
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast CancerRavi K Goyal, Sean D Candrilli, Susan Abughosh, et al.
Epilepsia|September 20, 2006
Interictal and postictal circadian and ultradian luteinizing hormone secretion in men with temporal lobe epilepsyMark Quigg, James M Kiely, Michael L Johnson, et al.
Drug, Healthcare and Patient Safety|February 27, 2020
Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid DepressionFarid Chekani, Holly M Holmes, Michael L Johnson, et al.
The Annals of Pharmacotherapy|November 28, 2015
Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With DepressionVishal Bali, Michael L Johnson, Hua Chen, et al.
Pageof 19

Showing results (101-110 of 190) with videos related to

Sort By:
Pageof 19
Exploratory Research in Clinical and Social Pharmacy|July 31, 2023
Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritisYinan Huang, Satabdi Chatterjee, Sandeep K Agarwal, et al.
Journal of the American Geriatrics Society|December 2, 2021
Risk of overactive bladder associated with cholinesterase inhibitors in dementiaPrajakta P Masurkar, Satabdi Chatterjee, Jeffrey T Sherer, et al.
Drugs & Aging|March 25, 2021
Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort StudySanika Rege, Ryan M Carnahan, Michael L Johnson, et al.
Journal of Alzheimer'S Disease : JAD|November 1, 2015
Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and HypertensionHemalkumar B Mehta, Vinay Mehta, Chu-Lin Tsai, et al.
Journal of Diabetes and Its Complications|May 30, 2025
Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes patientsZahra Majd, Hua Chen, Michael L Johnson, et al.
Journal of Psychiatric Research|August 5, 2019
Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's diseaseFarid Chekani, Holly M Holmes, Michael L Johnson, et al.
Cancers|June 27, 2024
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast CancerRavi K Goyal, Sean D Candrilli, Susan Abughosh, et al.
Epilepsia|September 20, 2006
Interictal and postictal circadian and ultradian luteinizing hormone secretion in men with temporal lobe epilepsyMark Quigg, James M Kiely, Michael L Johnson, et al.
Drug, Healthcare and Patient Safety|February 27, 2020
Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid DepressionFarid Chekani, Holly M Holmes, Michael L Johnson, et al.
The Annals of Pharmacotherapy|November 28, 2015
Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With DepressionVishal Bali, Michael L Johnson, Hua Chen, et al.
Pageof 19